Invesco Biotechnology & Genome ETF
PBE
86 hedge funds and large institutions have $171M invested in Invesco Biotechnology & Genome ETF in 2015 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 10 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 21
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
3% more capital invested
Capital invested by funds: $166M → $171M (+$5.66M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.26% less ownership
Funds ownership: 30.76% → 30.5% (-0.26%)
1% less funds holding
Funds holding: 87 → 86 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$1.67M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$989K |
| 3 |
LPL Financial
San Diego,
California
|
+$669K |
| 4 |
QA
Quantitative Advantage
Minnetonka,
Minnesota
|
+$594K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$371K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$2.46M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.64M |
| 3 |
AIG
American International Group
New York
|
-$1.16M |
| 4 |
Morgan Stanley
New York
|
-$972K |
| 5 |
VF
Virtu Financial
New York
|
-$698K |
PBE Hedge Fund Activity: Q2 2015 in Review
86 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q2 2015, worth a combined $171M — up 3.4% from $166M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new PBE positions and 10 closed out — a net gain of 1 holder — while 25 added to existing stakes and 21 trimmed.
The largest buyer was Wells Fargo, adding an estimated $1.67M. The largest seller was Jane Street, exiting entirely with an estimated $2.46M sold.
- 86 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q2 2015, down from 87 in Q1 2015.
- Funds reported $171M of Invesco Biotechnology & Genome ETF stock for Q2 2015, up 3.4% quarter-over-quarter.
- 11 funds opened new Invesco Biotechnology & Genome ETF positions in Q2 2015 and 10 closed out, a net change of +1 holder.
- The largest Invesco Biotechnology & Genome ETF buyer in Q2 2015 was Wells Fargo, an estimated $1.67M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q2 2015 was Jane Street, an estimated $2.46M sold.
Based on aggregated 13F filings for Q2 2015.